SCHEMBL139720

SCHEMBL139720

Cc1cccc(C#CC2=NOC3(CCN(c4nc(C)ccc4[N+](=O)[O-])C3)C2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 8/20 0.50
CYP3A4 P08684 2/20 0.43
ALDH1A1 P00352 7/20 0.32
MAPT P10636 4/20 0.32
MAPK1 P28482 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 3/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
HPGD P15428 2/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140437 0.95 GRM5 (0.51) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL140048 0.88 GRM5 (0.39) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL136375 0.85 GRM5 (0.38) GRM5ALDH1A1LMNA
SCHEMBL137515 0.85 GRM5 (0.41) GRM5CYP3A4ALDH1A1
SCHEMBL136175 0.85 GRM5 (0.38) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL135304 0.85 GRM5 (0.44) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL15673530 0.83 GRM5 (0.38) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL136179 0.83 GRM5 (0.42) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL134130 0.83 GRM5 (0.42) GRM5CYP3A4ALDH1A1MAPTMAPK1
SCHEMBL134526 0.82 GRM5 (0.42) GRM5CYP3A4ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580962-B2 Spiroheterocyclic compounds as mGlu5 antagonists RECORDATI IRELAND LTD. (IT) 2013-11-12 US claimed
US-20120059015-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD. (IT) 2012-03-08 US claimed
EP-2590985-B1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD (IE) 2014-05-14 EP disclosed
US-8580962-B2 Spiroheterocyclic compounds as mGlu5 antagonists RECORDATI IRELAND LTD. (IT) 2013-11-12 US disclosed
US-20120059015-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD. (IT) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059015-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS GRM5, GPR65, GRIK5 GRM5 1/4885CYP3A4 3928/4885ALDH1A1 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.